Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect.

Chen DM, Odueyungbo A, Csinady E, Gearhart L, Lehane P, Cheu M, Maho-Vaillant M, Prost-Squarcioni C, Hebert V, Houivet E, Calbo S, Caillot F, Golinski ML, Labeille B, Picard-Dahan C, Paul C, Richard MA, Bouaziz JD, Duvert-Lehembre S, Bernard P, Caux F, Alexandre M, Ingen-Housz-Oro S, Vabres P, Delaporte E, Quereux G, Dupuy A, Debarbieux S, Avenel-Audran M, D'Incan M, Bedane C, Bénéton N, Jullien D, Dupin N, Misery L, Machet L, Beylot-Barry M, Dereure O, Sassolas B, Benichou J, Musette P, Joly P; French Study Group on Autoimmune Bullous Diseases.

Br J Dermatol. 2019 Sep 5. doi: 10.1111/bjd.18482. [Epub ahead of print]

PMID:
31487383
2.

Modifications of the Transcriptomic Profile of Autoreactive B Cells From Pemphigus Patients After Treatment With Rituximab or a Standard Corticosteroid Regimen.

Hébert V, Petit M, Maho-Vaillant M, Golinski ML, Riou G, Derambure C, Boyer O, Joly P, Calbo S.

Front Immunol. 2019 Aug 7;10:1794. doi: 10.3389/fimmu.2019.01794. eCollection 2019.

3.

Long-Term Increase of Kcnn4 Potassium Channel Surface Expression on B Cells in Pemphigus Patients after Rituximab Treatment.

Caillot F, Derambure C, Berkani N, Riou G, Maho-Vaillant M, Calbo S, Joly P, Musette P.

J Invest Dermatol. 2018 Dec;138(12):2666-2668. doi: 10.1016/j.jid.2018.05.034. Epub 2018 Jul 2. No abstract available.

4.

First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial.

Joly P, Maho-Vaillant M, Prost-Squarcioni C, Hebert V, Houivet E, Calbo S, Caillot F, Golinski ML, Labeille B, Picard-Dahan C, Paul C, Richard MA, Bouaziz JD, Duvert-Lehembre S, Bernard P, Caux F, Alexandre M, Ingen-Housz-Oro S, Vabres P, Delaporte E, Quereux G, Dupuy A, Debarbieux S, Avenel-Audran M, D'Incan M, Bedane C, Bénéton N, Jullien D, Dupin N, Misery L, Machet L, Beylot-Barry M, Dereure O, Sassolas B, Vermeulin T, Benichou J, Musette P; French study group on autoimmune bullous skin diseases.

Lancet. 2017 May 20;389(10083):2031-2040. doi: 10.1016/S0140-6736(17)30070-3. Epub 2017 Mar 22.

PMID:
28342637
5.

Human regulatory B cells combine phenotypic and genetic hallmarks with a distinct differentiation fate.

Lin W, Cerny D, Chua E, Duan K, Yi JT, Shadan NB, Lum J, Maho-Vaillant M, Zolezzi F, Wong SC, Larbi A, Fink K, Musette P, Poidinger M, Calbo S.

J Immunol. 2014 Sep 1;193(5):2258-66. doi: 10.4049/jimmunol.1303214. Epub 2014 Jul 30.

6.

Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response.

Colliou N, Picard D, Caillot F, Calbo S, Le Corre S, Lim A, Lemercier B, Le Mauff B, Maho-Vaillant M, Jacquot S, Bedane C, Bernard P, Caux F, Prost C, Delaporte E, Doutre MS, Dreno B, Franck N, Ingen-Housz-Oro S, Chosidow O, Pauwels C, Picard C, Roujeau JC, Sigal M, Tancrede-Bohin E, Templier I, Eming R, Hertl M, D'Incan M, Joly P, Musette P.

Sci Transl Med. 2013 Mar 6;5(175):175ra30. doi: 10.1126/scitranslmed.3005166.

7.

IL-10 produced by activated human B cells regulates CD4(+) T-cell activation in vitro.

Bouaziz JD, Calbo S, Maho-Vaillant M, Saussine A, Bagot M, Bensussan A, Musette P.

Eur J Immunol. 2010 Oct;40(10):2686-91. doi: 10.1002/eji.201040673.

Supplemental Content

Loading ...
Support Center